Elena Ridloff Biography and Net Worth

Elena Ridloff is our Executive Vice President and Chief Financial Officer and has been with Acadia since April 2018 when she joined as Senior Vice President, Investor Relations. Previously, Ms. Ridloff was Vice President, Investor Relations at Alexion Pharmaceuticals and served as a member of the Operating Committee. In building and leading the investor relations function at Alexion, she played a key role in developing and executing the company’s investor relations strategy and outreach to broaden and strengthen the shareholder base. Prior to Alexion, Ms. Ridloff was Chief Executive Officer and Managing Member of BIOVISIO, an independent consulting firm providing strategic, financial and investor relations counsel to the life sciences industry. She was also a Managing Director at Maverick Capital, a hedge fund based in New York, and was responsible for investments in the biotechnology, pharmaceutical, medical device and life science sectors. She currently serves on the Boards of Directors of Kronos Bio and Kymera Therapeutics. Ms. Ridloff earned her B.A. in History and Sociology of Science from the University of Pennsylvania. She is also a CFA® charterholder.

What is Elena Ridloff's net worth?: The estimated net worth of Elena Ridloff is at least $188,487.95 as of April 30th, 2021. Ms. Ridloff owns 11,585 shares of ACADIA Pharmaceuticals stock worth more than $188,488 as of November 21st. This net worth estimate does not reflect any other assets that Ms. Ridloff may own. Learn More about Elena Ridloff's net worth.
How do I contact Elena Ridloff?: The corporate mailing address for Ms. Ridloff and other ACADIA Pharmaceuticals executives is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. ACADIA Pharmaceuticals can also be reached via phone at (858) 558-2871 and via email at [email protected]. Learn More on Elena Ridloff's contact information.
Has Elena Ridloff been buying or selling shares of ACADIA Pharmaceuticals?: Elena Ridloff has not been actively trading shares of ACADIA Pharmaceuticals within the last three months. Most recently, Elena Ridloff sold 1,032 shares of the business's stock in a transaction on Friday, April 30th. The shares were sold at an average price of $20.33, for a transaction totalling $20,980.56. Following the completion of the sale, the chief financial officer now directly owns 11,585 shares of the company's stock, valued at $235,523.05. Learn More on Elena Ridloff's trading history.
Who are ACADIA Pharmaceuticals' active insiders?: ACADIA Pharmaceuticals' insider roster includes Laura Brege (Director), Stephen Davis (CEO), James Kihara (Insider), Austin Kim (EVP), Elena Ridloff (CFO), Mark Schneyer (CFO), Srdjan Stankovic (President), and Brendan Teehan (COO). Learn More on ACADIA Pharmaceuticals' active insiders.
Are insiders buying or selling shares of ACADIA Pharmaceuticals?: During the last year, insiders at the biopharmaceutical company sold shares 26 times. They sold a total of 172,819 shares worth more than $3,042,092.93. The most recent insider tranaction occured on November, 19th when COO Brendan Teehan sold 10,329 shares worth more than $173,630.49. Insiders at ACADIA Pharmaceuticals own 28.3% of the company. Learn More about insider trades at ACADIA Pharmaceuticals.
Information on this page was last updated on 11/19/2024.

Elena Ridloff Insider Trading History at ACADIA Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/30/2021	Sell	1,032	$20.33	$20,980.56	11,585
2/4/2021	Sell	2,051	$50.61	$103,801.11	10,391
1/6/2021	Sell	1,016	$53.34	$54,193.44	4,917
4/29/2020	Sell	10,000	$50.74	$507,400.00	10,000
12/9/2019	Sell	36,000	$49.66	$1,787,760.00	36,000

Elena Ridloff Buying and Selling Activity at ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Company Overview

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Today's Range

Now: $16.27

$16.05

$16.39

50 Day Range

MA: $15.61

$14.29

$18.27

2 Week Range

Now: $16.27

$14.15

$32.59

Volume

1,087,297 shs

Average Volume

1,679,200 shs

Market Capitalization

$2.71 billion

P/E Ratio

20.86

Dividend Yield

N/A

Beta

0.38

“This Changes Everything” - Trump Hands Millions Massive IRS Gift

From Colonial Metals | Ad

Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…

>> YES! Send Me My FREE Gold Guide!